The clinical significance of autoantibodies in gastrointestinal malignancies: an overview

Bibliography

• BROLL R, DUCHROW M, OEVERMANN E et al.: p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int. J. Colorectal Dis. (2001) 16:22-27.
   PubMed Web of Science ®Google Scholar
• ZHANG JY, CASIANO CA, PENG XX et al.: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomarkers Prev. (2003) 12:136-143.
   PubMed Web of Science ®Google Scholar
• SHIMADA H, TAKEDA A, ARIMA M et al.: Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer (2000) 89:1677-1683.
   PubMed Web of Science ®Google Scholar
• SALEH J, KREISSLER-HAAG D, MONTENARH M: P53 autoantibodies from patients with colorectal cancer recognize common epitopes in the N- or C-terminus of p53. Int. J. Oncol. (2004) 25:1149-1155.
   PubMed Web of Science ®Google Scholar
• TAKEDA A, SHIMADA H, NAKAJIMA K et al.: Impact of circulating p53 autoantibody monitoring after endoscopic resection in mucosal gastric cancer. Endoscopy (2000) 32:740-741.
   PubMed Web of Science ®Google Scholar
• GANSAUGE S, GANSAUGE F, NEGRI G et al.: The role of anti-p53-autoantibodies in pancreatic disorders. Int. J. Pancreatol. (1996) 19:171-178.
   PubMedGoogle Scholar
• SHIOTA G, KISHIMOTO Y, SUYAMA A et al.: Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J. Hepatol.(1997) 27:661-668.
   PubMed Web of Science ®Google Scholar
• KONSTADOULAKIS M, SYRIGOS KN, ALBANOPOULOS C et al.: The presence of anti-carcinoembryonic antigen (CEA) antibodies in the sera of patients with gastrointestinal malignancies. J. Clin. Immunol. (1994) 14:310-313.
   PubMed Web of Science ®Google Scholar
• ALBANOPOULOS K, ARMACOLAS A, KONSTADOULAKIS M et al.: Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am. J. Gastroenterol. (2000) 95:1056-1061.
   PubMed Web of Science ®Google Scholar
• YAGIHASHI A, ASANUMA K, TSUJI N et al.: Detection of anti-livin antibody in gastrointestinal cancer patients. Clin. Chem. (2003) 49:1206-1208.
   PubMed Web of Science ®Google Scholar
• MEGLIORINO R, SHI FD, PENG XX et al.: Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect. Prev. (2005) 29:241-248.
   PubMedGoogle Scholar
• HAMANAKA Y, SUEHIRO Y, FUKUI M et al.: Circulating anti-muc1 IGG antibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer (2002) 103:97-100.
   Web of Science ®Google Scholar
• NAKAMURA H, HINODA Y, NAKAGAWA N et al.: Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J. Gastroenterol. (1998) 33:354-361.
   PubMed Web of Science ®Google Scholar
• REIPERT BM, TANNEBERGER S, PANNETA A et al.: Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer? Cancer Immunol. Immunother. (2005) 54:1038-1042.
   PubMed Web of Science ®Google Scholar
• KONSTADOULAKIS MM, SYRIGOS KN, LEANDROS M et al.: Autoantibodies in the serum of patients with gastric cancer: their prognostic importance. Hybridoma (1998) 17:431-435.
   PubMed Web of Science ®Google Scholar
• WARD RL, HAWKINS NJ, COOMBER D et al.: Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum. Immunol. (1999) 60:510-515.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI M, CHEN W, BYRD DR et al.: Antibody to ras proteins in patients with colon cancer. Clin. Cancer Res. (1995) 1:1071-1077.
   PubMed Web of Science ®Google Scholar
• WANG Y, WU XJ, ZHAO AL et al.: Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun. (2004) 4:11-17.
   PubMedGoogle Scholar
• SU Y, QIAN H, ZHANG J et al.: The diversity expression of p62 in digestive system cancers. Clin. Immunol. (2005) 116(2)׃118-123.
   PubMed Web of Science ®Google Scholar
• KASTAN MB, ONYEKWERE O, SIDRANSKY D et al.: Participation of p53 protein in the cellular response to DNA damage. Cancer Res. (1991) 51:6304-6311.
   PubMed Web of Science ®Google Scholar
• YONISH-ROUACH E, RESNITZKY D, LOTEM J et al.: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (1991) 352:345-347.
   PubMed Web of Science ®Google Scholar
• HAMMEL P, LEROY-VIARD K, CHAUMETE MT et al.: Correlations between p53-protein accumulation, serum antibodies and mutation in colorectal cancer. Int. J. Cancer (1999) 81:712-718.
   PubMed Web of Science ®Google Scholar
• POLGE A, BOURGAUX JF, BANCEL E et al.: p53 and follow-up of colorectal adenocarcinomas. Dig. Dis. Sci. (1998) 43:1434-1442.
   PubMed Web of Science ®Google Scholar
• FENOGLIO-PREISER CM, WANG J, STEMMERMANN GN et al.: p53 and gastric carcinoma: a review. Hum. Mutat. (2003) 21:258-370.
   PubMed Web of Science ®Google Scholar
• RYDER SD, RIZZI PM, VOLKMANN M et al.: Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J. Clin. Pathol. (1996) 49:295-299.
   PubMed Web of Science ®Google Scholar
• DAVIDOFF AM, IGLEHART JD, MARKS JR: Immune response to p53 is dependent upon p53/HS70 complexes in breast cancer. Proc. Natl. Acad. Sci. USA (1992) 89:3439-3442.
   PubMed Web of Science ®Google Scholar
• SOUSSI T: p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res. (2000) 60:1777-1788.
   PubMed Web of Science ®Google Scholar
• FORSLUND A, KRESSNER U, LINDMARK G et al.: Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas. Int. J. Oncol. (2001) 19:501-506.
   PubMed Web of Science ®Google Scholar
• WINTER SF, MINNA JD, JOHNSON BE et al.: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. (1992) 52:4168-4174.
   PubMed Web of Science ®Google Scholar
• PARASHAR K, SOBTI RC: A study on protein p53 and anti-p53 antibodies in the sera of patients with oesophageal cancer. Mutat. Res. (1998) 422:271-277.
   Google Scholar
• BARNES DM, HANDY AM, GILLETT CE et al.: Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet (1992) 340:259-263.
   PubMed Web of Science ®Google Scholar
• HALL PA, MCKEE PH, DU P et al.: High levels of p53 protein in UV-irradiated normal human skin. Oncogene (1993) 8:203-207.
   PubMed Web of Science ®Google Scholar
• BAAS IO, MULDER JW, OFFERHAUS JA et al.: An evaluation of six antibodies for immunohistochemistry of mutant p53 product in archival colorectal neoplasms. J. Pathol. (1994) 172:5-12.
   Google Scholar
• BARNES DP, HANDLY AM, GILLET CE: Abnormal expression of wild type p53 protein in normal cell of cancer family patient. Lancet (1992) 340:259-263.
   PubMed Web of Science ®Google Scholar
• LANE DP, CRAWFORD LV: T antigen is bound to a host protein in SV40 transformed cells. Nature (1979) 278:261-263.
   PubMed Web of Science ®Google Scholar
• BENNETT WP, COLBY TV, TRAVIS WD et al.: P53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. (1993) 53:4817-4822.
   PubMed Web of Science ®Google Scholar
• PREUDHOMME C, LUBIN R, LEPELLEY P et al.: Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodyplastics syndromes and acute myeloid leukemia. Leukemia (1994) 8:1589-1591.
   PubMed Web of Science ®Google Scholar
• SHIMADA H, OCHIAI T, NOMURA F: Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors. Cancer (2003) 97:682-689.
   PubMed Web of Science ®Google Scholar
• RAEDLE J, OREMEK G, WELKER M et al.: P53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas (1996) 13:241-246.
   PubMed Web of Science ®Google Scholar
• EDIS C, KAHLER C, KLOTZ W et al.: A comparison between a-fetoprotein and p53 antibodies in the diagnosis of hepatocellular carcinoma. Transplant. Proc. (1998) 30:780-781.
   Web of Science ®Google Scholar
• SAFFROY R, LELONG JC, AZOULAY D et al.: Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br. J. Cancer (1999) 79:604-610.
   PubMed Web of Science ®Google Scholar
• NOMURA F: Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors. Cancer (2003) 97:682-689.
   PubMed Web of Science ®Google Scholar
• KOZLOWSKI M, KOVALCHUK O, NIKLINSKI J et al.: Circulating anti-p53 antibodies in esophageal cancer patients. Folia Histochem. Cytobiol. (2001) 39:173-174.
   PubMedGoogle Scholar
• TANG R, KO MG, WANG JY et al.: Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int. J. Cancer (2001) 94:85-863.
   Google Scholar
• SHIMIZU K, UEDA Y, YAMAGISHI H: Titration of serum p53antobodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer (2005) 8:214-219.
   PubMedGoogle Scholar
• SHIMADA H, OCHIAI T, BIELICKI D et al.: Clinicopathological characteristics of colorectal cancer and serum anti-p53 antibodies. Pol. J. Pathol. (1999) 50:77-81.
   Google Scholar
• TAKEDA A, SHIMADA H, NAKAJIMA K et al.: Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. Eur. J. Surg. (2001) 167:50-53.
   PubMedGoogle Scholar
• SHIMADA H, OKAZUMI S, TAKEDA A et al.: Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg. Today (2001) 31:591-596.
   PubMed Web of Science ®Google Scholar
• HAGIWARA N, ONDA M, MIYASHITA M et al.: Detection of circulating anti-p 53 antibodies in esophageal cancer patients. J. Nippon Med. Sch. (2000) 67:110-117.
   PubMedGoogle Scholar
• RALHAN R, ARORA S, KANT TC et al.: Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int. J. Cancer (2000) 85:791-795.
   PubMed Web of Science ®Google Scholar
• BERGSTROM S, DREILICH M, WAGENIUS G et al.: The presence of anti-p53 antibodies in sera from patients with esophageal carcinoma: correlation to treatment, tumor volume and survival. In Vivo (2004) 18:615-620.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA K, SUZUKI T, SHIMADA H et al.: Detection of preoperative serum anti-p53 antibodies in gastric cancer. Tumor Biol. (1999) 20:147-152.
   PubMed Web of Science ®Google Scholar
• HOUBIERS JG, VAN DER BURG SH, VAN DE WATERING LM et al.: Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br. J. Cancer (1995) 72:637-664.
   PubMed Web of Science ®Google Scholar
• LECHPAMMER M, LUKAC J, LECHPAMMER S et al.: Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int. J. Colorectal Dis. (2004) 19:114-120.
   PubMed Web of Science ®Google Scholar
• SHIOTA G, ISHIDA M, NOGUCHI N et al.: Clinical significance of serum P53 antibody in patients with gastric cancer. Res. Commun. Mol. Pathol. Pharmacol. (1998) 99:41-51.
   PubMed Web of Science ®Google Scholar
• MAEHARA Y, KAKEJI Y, WATANABE A et al.: Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer (1999) 85:302-308.
   PubMed Web of Science ®Google Scholar
• WURL P, WEIGMANN F, MEYE A et al.: Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand. J. Gastroenterol. (1997) 32:1147-1151.
   PubMed Web of Science ®Google Scholar
• SHIMADA H, NABEYA Y, OKAZUMI S et al.: Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery (2002) 132:41-47.
   PubMed Web of Science ®Google Scholar
• WANG MH, LI YP, WANG XD et al.: Correlation between serum p53 antibody and chemosensitivity in patients with esophageal cancer. Ai Zheng (2004) 23:467-470.
   PubMed Web of Science ®Google Scholar
• CARBONE D: Smoking habit and cancer. Am. J. Med. (1992) 93(Suppl. 1A):13S-17S.
   Google Scholar
• TAKEDA A, SHIMADA H, NAKAJIMA K et al.: Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int. J. Clin. Oncol. (2001) 6:45-49.
   PubMed Web of Science ®Google Scholar
• SHIBATA Y, KOTANAGI H, ANDOH H et al.: Detection of circulating anti p53 antibodies in patients with colorectal carcinoma and the antibody’s relation to clinical factors. Dis. Colon Rectum (1996) 39:1269-1274.
   PubMed Web of Science ®Google Scholar
• SHIMADA H, NAKAJIMA K, OCHIAI T et al.: Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers. Oncol. Rep. (1998) 5:871-874.
   PubMed Web of Science ®Google Scholar
• TAKEDA A, SHIMADA H, NAKAJIMA K et al.: Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring. Gan To Karagu Ryoho (1999) 26:2189-2194.
   PubMedGoogle Scholar
• TAKEDA A, AKIHIKO H, NAKAJIMA K et al.: Detection of serum p53 antibodies in mucosal colorectal cancer and negative conversion after endoscopic resection. J. Clin. Gastroenterol. (1999) 28:153-154.
   PubMed Web of Science ®Google Scholar
• VOLKMANN M, MULLER M, HOFMANN WJ et al.: The humoral immune response to p53 in patients with hepatocellular carcinoma in specific for malignancy and independent of the alpha-fetoprotein status. Hepatology (1993) 18:559-565.
   PubMed Web of Science ®Google Scholar
• RAEDLE J, ROTH WK, OREMEK G et al.: Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig. Dis. Sci. (1995) 40:2587-2594.
   PubMed Web of Science ®Google Scholar
• BENARD J, DOUC-RASY S, AHOMADEGBE JC: Tp53 family members and human cancers. Hum. Mutat. (2003) 21:182-191.
   PubMed Web of Science ®Google Scholar
• CIOFFI M, RIEGLER G, VIETRI MT et al.: Serum p53 antibodies in patients affected with ulcerative colitis. Inflamm. Bowel Dis. (2004) 10:606-611.
   PubMed Web of Science ®Google Scholar
• CAWLEY HM, MELTZER SJ, DE BENEDETTI VM et al.: Anti-p53 antibodies in patients with Barretts oesophagus or oesophageal carcinoma can predate cancer diagnosis. Gastrenterology (1998) 115:19-27.
   PubMed Web of Science ®Google Scholar
• LI Y, KARJALAINEN A, KOSKINEN H et al.: P53 autoantibodies predict subsequent development of cancer. Int. J. Cancer (2005) 114:157-160.
   PubMed Web of Science ®Google Scholar
• RAEDLE J, OREMEK G, ROTH WK et al.: Anti-p53 autoantibodies in hepatitis c virus-infected patients. Anticancer Res. (1997) 17:3079-3082.
   PubMed Web of Science ®Google Scholar
• TAKEDA A, NAKAJIMA K, SHIMADA H et al.: Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. J. Surg. Oncol. (1999) 71:112-116.
   PubMed Web of Science ®Google Scholar
• MAETA M, SAITO H, OKA S et al.: Mutated p53 in tumors, mutant p53 and p53-specific antibodies in the circulation in patients with gastric cancer. J. Exp. Cancer Res. (2000) 19:489-495.
   PubMed Web of Science ®Google Scholar
• WU CW, LIN YY, CHEN GD et al.: Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br. J. Cancer (1999) 80:483-488.
   PubMed Web of Science ®Google Scholar
• BERGQVIST AS, BERGQVIST M, BRATTSTROM D et al.: Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. Anticancer Res. (2001) 21:4141-4145.
   PubMed Web of Science ®Google Scholar
• VAN DER BURG SH, DE COCK K, MENON AG et al.: Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur. J. Immunol. (2001) 31:146-155.
   PubMed Web of Science ®Google Scholar
• TAKEDA A, SHIMADA H, NAKAJIMA K et al.: Clinical significance of serum p53 antibody detection in a chemosensitivity assay in case of human colorectal cancer. Gan To Kagaku Ryoho (2000) 27:876-888.
   Google Scholar
• BEAUCHEMIN N, BENCHIMOL S, COURNOYER D et al.: Isolation and characterization of full length functional cDNA clones for human carcinoembryonic antigen. Mol. Cell. Biol. (1987) 7:3221-3230.
   PubMed Web of Science ®Google Scholar
• NIGHAM K, SAVAGE F, STAMP GW et al.: Loss of cell-cell and cell-matrix adhesion molecules in colorectal cancer. J. Cancer (1993) 68:507-513.
   Web of Science ®Google Scholar
• OIKAWA S, IMAJO S, NOGUCHI T et al.: The carcinoembryonic antigen contains multiple immunoglobulin-like domains. Biochem. Biophys. Res. Commun. (1987) 144:634-648.
   PubMed Web of Science ®Google Scholar
• STAAB HJ, ANDERER FA, STUMPF E et al.: Prognostic value of circulating immune complexes of carcinoembryonic antigen (CEA) in patients with adenocarcinoma of the gastrointestinal tract. J. Clin. Chem. Biochem. (1980) 18:175-181.
   PubMedGoogle Scholar
• METERRISIAN S, FORD R, TOTH CA: Carcinoembryonic antigen is an adhesion molecule for colorectal carcinomas. Proc. Am. Assoc. Cancer Res. (1991) 32:72.
   Google Scholar
• CLARK GW, IRELAND AP, HAGEN JA et al.: Carcinoembryonic antigen measurements in the management of esophageal cancer: an indicator of subclinical recurrence. Am. J. Surg. (1995) 170:597-600.
   PubMed Web of Science ®Google Scholar
• CASTALDI F, MARINO M, BENEDUCE L et al.: Detection of circulating CEA-IgM complexes in early stage colorectal cancer. Int. J. Biol. Markers (2005) 20:204-208.
   PubMed Web of Science ®Google Scholar
• STAAB HJ, ANDERER FA, BRUMENDOR FT et al.: Prognostic value of preoperative serum CEA level as a prognostic indicator in colorectal carcinoma. Br. J. Cancer (1981) 44:652-662.
   PubMed Web of Science ®Google Scholar
• CARRIQUIRY L, PINEYRO A: Should Carcinoembryonic antigen be used in the management of patients with colorectal cancer. Dis. Colon Rectum (1999) 42:921-929.
   PubMed Web of Science ®Google Scholar
• LAMERZ R: Role of tumor markers, cytogenetics. Ann. Oncol. (1999) 10:145-149.
   PubMed Web of Science ®Google Scholar
• OKADA M, NISHIO W, SAKAMOTO T et al.: Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann. Thorac. Surg. (2004) 78:1004-1009.
   PubMed Web of Science ®Google Scholar
• HERRERA MA, CHU TM, HOLYOKE ED: CEA is a prognostic and monitoring test in clinical complete resection of colorectal carcinoma. Ann. Surg. (1976) 183:5-9.
   PubMed Web of Science ®Google Scholar
• ZAMCHECK N: CEA in diagnosis, prognosis, detection of recurrence and evaluation of therapy of colorectal cancer. In: Clinical Application of CEA Assay. Krebs BP, Lalanne CM, Schneider M (Eds), Excerpta Medica, Amsterdam, The Netherlands (1978):64-79.
   Google Scholar
• MAVLIGIT GM, STUCKEY S: Colorectal carcinoma. Evidence for circulating CEA-anti-CEA complexes. Cancer (1983) 52:146-149.
   PubMed Web of Science ®Google Scholar
• GOLD P: Circulating antibodies against carcinoembryonic antigens of the human digestive system. Cancer (1967) 20:1663-1667.
   Web of Science ®Google Scholar
• GOLD JM, BANJO C, FREEDMAN SO et al.: Immunochemical studies of the intramolecular heterogeneity of the carcinoembryonic antigen (CEA) of the human digestive system. J. Immunol. (1973) 111:1872-1879.
   PubMed Web of Science ®Google Scholar
• YCHOU M, PELEGRIN A, FAUROUS P et al.: Phase-I/II radio immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab’)2 in patients with non-resectable liver metastases from colorectal cancer. Int. J. Cancer (1998) 75:615-619.
   PubMed Web of Science ®Google Scholar
• CORNY RM, ALLEN KO, LEE S et al.: Human autoantibodies to carcinoembrionic (CEA) induced by a vaccinia-CEA vaccine. Clin. Cancer Res. (2000) 6(1):34-41.
   PubMed Web of Science ®Google Scholar
• FRENOY N, SCHAUFFLER J, CAHOUR A et al.: Natural antibodies against carcinoembryonic antigen (CEA) and a related antigen, NCA, in human sera. Anticancer Res. (1987) 7:1229-1233.
   PubMed Web of Science ®Google Scholar
• BURTIN P: The carcinoembryonic antigen (CEA) of the digestive system and the antigens cross-reacting with it. Ann. Immunol. (1978) 129:185-198.
   Google Scholar
• HOLBURN AM, MATCH JP, MACDONALD D et al.: Studies of the association of the A, B and Lewis blood group antigens with CEA. Immunology (1974) 26:831-843.
   PubMed Web of Science ®Google Scholar
• URA Y, OCHI Y, HAMAZU M et al.: Studies on circulating antibody against carcinoembryonic antigen (CEA) and CEA-like antigen in cancer patients. Cancer Lett. (1985) 25:283-295.
   PubMed Web of Science ®Google Scholar
• SCHOENFIELD Y: Autoantibodies in the sera of cancer patients. Cancer (1991) 12:353-359.
   Google Scholar
• PRESSMAN D, CHU TM, GROSSBERG AL: Carcinoembryonic antigen-binding immunoglobulin isolated from normal human serum by affinity chromatography. J. Natl. Cancer Inst. (1980) 12:195-197.
   Google Scholar
• SYRIGOS KN, KARAYIANNAKIS AJ, ZBAR A: Mucins as immunogenic targets in cancer. Anticancer Res. (1999) 19(6B):5239-5244.
   PubMed Web of Science ®Google Scholar
• AJIOKA Y, WATANABE H, JASS JR: MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas. J. Clin. Pathol. (1997) 50:417-421.
   PubMed Web of Science ®Google Scholar
• GENDLER SJ, SPICER AP: Epithelial mucin genes. Annu. Rev. Physiol. (1995) 57:607-634.
   PubMed Web of Science ®Google Scholar
• LAPANSEE L, PANQUETTE Y, BLEAU G: Allelic polymorphism and chromosomal localization of the human oviductin gene (MUC9). Fertil. Steril. (1997) 68:702-708.
   PubMed Web of Science ®Google Scholar
• SHANKAR V, PICTAN P, EDDY JR et al.: Localization of human mucin gene (MUC8) and the cloning of the cDNA corresponding to the carboxy terminus. Am. J. Respir. Cell Mol. Biol. (1997) 16:232-241.
   PubMed Web of Science ®Google Scholar
• WILLIAMS SJ, MCGUCKIN MA, GOTLEY DC et al.: Two novel mucin genes down-regulated in colorectal cancer identified by differential display. Cancer Res. (1999) 59:4083-4089.
   PubMed Web of Science ®Google Scholar
• VON MENSDORFF-POUILLY S, SNIJDEWINT FG, VERSTRAETEN AA et al.: Human MUC1 mucin: a multifaceted glycoprotein. Int. J. Biol. Markers (2000) 15(4):343-356.
   PubMed Web of Science ®Google Scholar
• CARRATO C, BALAGUE C, DE BOLOS C et al.: Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. Gastroenterology (1994) 107(1):160-172.
   PubMed Web of Science ®Google Scholar
• VAN GONG N, AUBERT JP, GROSS MS et al.: Assignment of human tracheobronchial mucin gene(s) to 11p15 and a tracheobronchial mucin-related sequence to chromosome 13. Hum. Genet. (1990) 86:167-172.
   PubMed Web of Science ®Google Scholar
• BUISINE MP, DESSEYN JP, PORCHET N et al.: Genomic organization of the 3-region of the MUC5AC mucin gene: additional evidence for a common ancestral gene for the 11p15.5 mucin gene family. Biochem. J. (1998) 332:729-738.
   PubMed Web of Science ®Google Scholar
• KOCER B, SORAN A, ERDOGAN S et al.: Expression of MUC5AC in colorectal carcinoma and relationship with prognosis. Pathol. Int. (2002) 52:470.
   PubMed Web of Science ®Google Scholar
• YONEZAWA S, SATO E: Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol. Int. (1997) 47:813-830.
   PubMed Web of Science ®Google Scholar
• BALAQUE C, GAMBUS G, CARRATO C et al.: Altered expression of MUC2, MUC4 and MUC5 mucin genes in pancreas tissues and cancer cell lines. Gastroenterology (1994) 106:1054-1061.
   PubMed Web of Science ®Google Scholar
• TERADA T, OHTA T, SASAKI M et al.: Expression of MUC apomucin in normal pancreas and pancreatic tumors. J. Pathol. (1996) 180:160-165.
   PubMed Web of Science ®Google Scholar
• YONEZAWA S, HORINOUCHI M, OSAKO M et al.: Gene expression of gastric mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behaviour of the tumor. Pathol. Int. (1999) 49:45-54.
   PubMed Web of Science ®Google Scholar
• BALDUS SE, MONIQ SP, ARKENAU V et al.: Correlation of MUC5AC immunoreactivity with histopathological subtypes and prognosis of gastric carcinoma. Ann. Surg. Oncol. (2002) 9(9):887-893.
   PubMed Web of Science ®Google Scholar
• NIWA T, IKEHARA Y, NAKANISHI H et al.: Mixed gastric- and intestinal-type metaplasia is formed by cells with dual intestinal and gastric differentiation. J. Histochem. Cytochem. (2005) 53(1):75-85.
   PubMed Web of Science ®Google Scholar
• GRINSTEAD JS, KOGARTY RR, KRANTZ MJ et al.: Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions. Biochemistry (2002) 41(31):9946-9961.
   PubMed Web of Science ®Google Scholar
• KOTERA Y, FONTENOT JD, PECHER G et al.: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. (1994) 54:2856-2860.
   PubMed Web of Science ®Google Scholar
• KOCER B, MCKOLANIS J, SORAN A: Humoral immune response to MUC5AC in patients with colorectal carcinoma. BMC Gastroenterol. (2006) 6:4.
   PubMed Web of Science ®Google Scholar
• AMBROSINI S, ADIDA C, ALTIERI DC: A novel anti apoptosis gene, surviving, expressed in cancer and lymphoma. Nat. Med. (1997) 3:917-921.
   PubMed Web of Science ®Google Scholar
• IKEGUCHI M, KAIBARA N: Survivin messenger RNA expression is a good prognostic biomarker for esophageal carcinoma. Br. J. Cancer (2002) 87:883-887.
   PubMed Web of Science ®Google Scholar
• MENG H, LU C, MABUCHI H, TANIGAWA N: Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett. (2004) 216(2):147-155.
   PubMed Web of Science ®Google Scholar
• MENG H, LU CD, SUN YL et al.: Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J. Gastroenterol. (2004) 10(22):3245-3250.
   PubMed Web of Science ®Google Scholar
• MENG H, LU D, DAI DJ et al.: Elevated expression level of wild-type survivin in gastric cancer promotes in vitro docetaxel-resistance. Zhonghua Yi Xue Za Zhi (2004) 84(24):2060-2063.
   PubMedGoogle Scholar
• JIANG ZM, YAO HR, ZHAN J et al.: Expression and significance of survivin in colon cancer. Ai Zheng (2004) 23(11 Suppl.):1414-1417.
   PubMedGoogle Scholar
• CHEN WC, LIU Q, FU JX et al.: Expression of survivin and its significance in colorectal cancer. World J. Gastroenterol. (2004) 10(19):2886-2889.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI Y, YUKIUE H, SASAKI H et al.: Developmentally regulated expression of survivin in the human thymus. Hum. Immunol. (2002) 63:101-107.
   PubMed Web of Science ®Google Scholar
• TAMM I, WANG Y, SAUSVILLE E et al.: IAP family protein survivin inhibits caspace activity and apoptosis induced by FAS(CD95) Bax, caspaces, and anticancer drugs. Cancer Res. (1998) 58:6315-6320.
   Google Scholar
• MILLER LK: An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. (1999) 9:323-328.
   PubMed Web of Science ®Google Scholar
• ALTIERI DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. (2001) 7:542-547.
   PubMed Web of Science ®Google Scholar
• REED JC, BISCHOFF JR: Ringing chromosomes through cell division: and survivin’ the experience. Cell (2000) 102:545-548.
   PubMed Web of Science ®Google Scholar
• GIODINI A, KALLIO MJ, WALL NR et al.: Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. (2002) 62:2462-2467.
   PubMed Web of Science ®Google Scholar
• IKEGUCHI M, LIU J, KAIBARA N: Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis (2002) 7:23-29.
   PubMed Web of Science ®Google Scholar
• PAPAPETROPOULOS A, FULTON D, MAHBOUBI K et al.: Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/surviving pathway. J. Biol. Chem. (2000) 275:9102-9105.
   PubMed Web of Science ®Google Scholar
• ROHAYEM J, DIESTELKOETTER P, WEIGLE B et al.: Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. (2000) 60:1815-1817.
   PubMed Web of Science ®Google Scholar
• YAGIHASHI A, ASAMMA K, NAKAMURA M et al.: Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin. Chem. (2001) 9:47:1729-1731.
   Google Scholar
• KASOF GM, GOMES BC: Livin, a novel inhibitor of apoptosis protein family member. J. Biol. Chem. (2001) 276:3238-3246.
   PubMed Web of Science ®Google Scholar
• VUCIC D, STENNICKE HR, PISABARRO MT et al.: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. (2000) 10:1359-1366.
   PubMed Web of Science ®Google Scholar
• LIN JH, DENG G, HUANG Q et al.: KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem. Biophys. Res. Commun. (2000) 279:820-831.
   PubMed Web of Science ®Google Scholar
• MOLLER P, KORETZ K, LEITHAUSER F et al.: Expression of APO-1(CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer (1994) 57(3):371-377.
   PubMed Web of Science ®Google Scholar
• HALL PA, COATES PJ, ANSARI B et al.: Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J. Cell Sci. (1994) 107:3569-3577.
   PubMed Web of Science ®Google Scholar
• BENNETT MW, O’CONNELL J, O’SULLIVAN GC et al.: Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover. Dis. Esophagus (1999) 12:90-98.
   PubMed Web of Science ®Google Scholar
• OWEN-SHAUB LB, ZHANG W, CUSACK JC et al.: Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. (1995) 15:3032-3040.
   PubMed Web of Science ®Google Scholar
• WYLLIE AH, BELLAMY CO, BUBB VJ et al.: Apoptosis and carcinogenesis. Br. J. Cancer (1998) 80(Suppl. 1):34-37.
   Google Scholar
• BENNETT MW, O’CONNELL J, HOUSTON A et al.: Fas ligand upregulation is an early event in colonic carcinogenesis. J. Clin. Pathol. (2001) 54:598-604.
   PubMed Web of Science ®Google Scholar
• O’CONNELL J, BENNETT MW, O’SULLIVAN GC et al.: Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. (1998) 186:240-246.
   PubMed Web of Science ®Google Scholar
• SUZUKI A, ENARI M, EGUSHI Y et al.: Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. EMBO J. (1996) 133:335-343.
   Google Scholar
• LEE J, RICHBURG JH, YOUNKIN SC et al.: The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology (1997) 138:2081-2088.
   PubMed Web of Science ®Google Scholar
• ADACHI M, SUEMATSU S, KONDO T et al.: Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. (1995) 11:294-300.
   PubMed Web of Science ®Google Scholar
• RESTIFO NP: Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. (2000) 6:493-495.
   PubMed Web of Science ®Google Scholar
• ALTZANAUER F, VON GUNTEN S, SPATH P et al.: Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. Allergy Clin. Immunol. (2003) 112:1185-1190.
   Google Scholar
• STELLAMOR MT, REIPERT BM, POELL M et al.: Biological activity of antibodies against members of the TNF receptor superfamily that are present in normal human IgG. FASEB J. (2002) 16:A1247.
   Google Scholar
• VIARD I, WEHRLI P, BULLANI R et al.: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (1998) 1282:490-493.
   Google Scholar
• PRASAD NK, PAPOFF G, ZEUNER A et al.: Therapeutic preparations of normal polyspecific IgG (IVIG) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action IVIG involving the Fas apoptotic pathway. J. Immunol. (1998) 161:3781-3790.
   PubMed Web of Science ®Google Scholar
• YADIN O, SAROV B, NAGGAN L: Natural antibodies in serum of healthy women. A five year follow up. Clin. Exp. Immunol. (1989) 75:402-405.
   PubMed Web of Science ®Google Scholar
• NJEMINI R, MEYERS I, DEMANET C: The prevalence of auto-antibodies in an elderly sub-Saharan African population. Clin. Exp. Immunol. (2002) 127:99-106.
   PubMed Web of Science ®Google Scholar
• BOOTSMA H, SPRONK PE, HUMMEL EJ et al.: Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. Scand. J. Rheumatol. (1996) 25:352-359.
   PubMed Web of Science ®Google Scholar
• SOLANS-LAQUÉ R, PÉREZ-BOCANEGRA C, SALUD-SALVIA A et al.: Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes. Lupus (2004) 13(3):159-164.
   PubMed Web of Science ®Google Scholar
• SYRIGOS KN, CHARALAMBOPOULOS A, PLIARCHOPOULOU K et al.: The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. (2000) 20:4351-4354.
   PubMed Web of Science ®Google Scholar
• IMAI H, NAKANO Y, OCHS RH et al.: Nuclear antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am. J. Pathol. (1992) 140:859-870.
   Web of Science ®Google Scholar
• IMAI H, NAKANO Y, KIYOSAWA K et al.: Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer (1993) 71:26-35.
   PubMed Web of Science ®Google Scholar
• HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57-70.
   PubMed Web of Science ®Google Scholar
• SHUN LV, ZHANG J, JIN WU et al.: Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. Immunol. Lett. (2005) 99:217-227.
   PubMed Web of Science ®Google Scholar
• MOY PM, HOLMES EC, GOLUB SH: Depression of natural killer cell cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res. (1985) 45:57-60.
   PubMed Web of Science ®Google Scholar
• LE LANN AD, FOURNIE GJ, BOISSIER L, TOUTAIN PL, BENOIST H: In vitro inhibition of natural-killer-mediated lysis by chromatin fragments. Cancer Immunol. Immunother. (1994) 39:185-192.
   PubMed Web of Science ®Google Scholar
• BELL DA, MORRISON B: The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin. Immunol. Immunopathol. (1991) 60:13-26.
   PubMedGoogle Scholar
• KOZYR AV, SASHCHENKO LP, KOLESNIKOV AV et al.: Anti-DNA autoantibodies reveal toxicity to tumor cell lines. Immunol Lett. (2002) 80:41-47.
   PubMed Web of Science ®Google Scholar
• ALARCON-SEGOVIA D, RUIZ-ARGUELLES A, LLORENTE L: Broken dogma: penetration of autoantibodies into living cells. Immunol. Today (1996) 17:163-164.
   Web of Science ®Google Scholar
• RUIZ-ARGUELLES A, PEREZ-ROMANO B, ALARCON-SEGOVIA D et al.: Penetration of anti-DNA antibodies into immature live cells. J. Autoimmun. (1998) 11:547-556.
   PubMed Web of Science ®Google Scholar
• SHUSTER AM, GOLOLOBOV GV, KVASHUK OA et al.: DNA hydrolyzing autoantibodies. Science (1992) 256:665-667.
   PubMed Web of Science ®Google Scholar
• DUBROVSKAYA VV, ANDRYUSHKOVA AS, KUZNETSOVA IA et al.: DNA hydrolyzing autoantibodies from sera of autoimmune-prone MRL/MpJ-Ipr mice. Biochemistry (2003) 68:1081-1088.
   PubMed Web of Science ®Google Scholar
• SCANLAN MJ, SIMPSON AJ, OLD LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun. (2004) 4:1-14.
   PubMedGoogle Scholar
• CHEN YT, SCANLAN MJ, SAHIN U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA (1997) 94:1914-1918.
   PubMed Web of Science ®Google Scholar
• FUGITA S, WADA H, JUNGBLUTH AA et al.: NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin. Cancer Res. (2004) 10:6551-6558.
   PubMed Web of Science ®Google Scholar
• LI M, YUAN YH, HAN Y et al.: Expression profile of cancer-testis genes in 121 humoral colorectal cancer tissue and adjacent normal tissue. Clin. Cancer Res. (2005) 11:1809-1814.
   PubMed Web of Science ®Google Scholar
• WANG Y, WU XJ, ZHAO AL et al.: Cancer-testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun. (2004) 4:11.
   PubMedGoogle Scholar
• AKCAKANAT A, KANDA T, KOYAMA Y et al.: NY-ESO-1 expression and its serum mmunoreactivity in esophageal cancer. Cancer Chemother. Pharmacol. (2004) 54:95-100.
   PubMed Web of Science ®Google Scholar
• WU XJ, WANG Y, JI JF: Analysis of CT antigen expression and humoral immunogenicity of NY-ESO-1 protein in gastric carcinoma. Beijing Da Xue Xue Bao (2005) 37(3):252-256.
   PubMedGoogle Scholar
• SCANLAN MJ, WELT S, GORDON CM et al.: Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. (2002) 62:4041-4047.
   PubMed Web of Science ®Google Scholar
• WALDE A, KUBUSCHOK B, IMIG J et al.: Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int. J. Cancer (2006) 119(1):117-125.
   PubMed Web of Science ®Google Scholar
• STOCKERT E, JAGER E, CHEN YT et al.: A survey of the humoral immune response of cancer patients to a panel of human tumors antigens. J. Exp. Med. (1998) 187:1349-1354.
   PubMed Web of Science ®Google Scholar
• BALZAR M, WINTER MJ, DE BOER CJ et al.: The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. (1999) 77:699.
   PubMed Web of Science ®Google Scholar
• SHETYE J, CHRISTENSSON B, RUBIO C et al.: The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues. Anticancer Res. (1989) 9:395.
   PubMed Web of Science ®Google Scholar
• MOSOLITIS S, HARMENBERG U, RUDEN U et al.: Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol. Immunother. (1999) 47(6):315-320.
   PubMed Web of Science ®Google Scholar
• SYRIGOS KN, CHARALAMPOPOULOS A, PLIARCHOPOULOU K et al.: Prognostic significance of autoantibodies against tropomyosin in patients with colorectal adenocarcinoma. Hybridoma (1999) 18(6):543-546.
   PubMed Web of Science ®Google Scholar
• SYRIGOS KN, CHARALAMPOPOULOS A, KONSTANTOULAKIS MM, KARAYIANNAKIS A, TSIBLOULIS V, PEVERETOS P: Autoantibodies against cardiolipin in the serum of patients with colorectal adenocarcinoma: their prognostic significance. Eur. Surg. Res. (1998) 30(1):55-60.
   PubMed Web of Science ®Google Scholar
• SYRIGOS KN, KONSTANTOULAKIS MM, FYSSAS I, KATSILAMBROS N, GOLEMATIS BC: Autoantibodies against insulin and beta-islet cells in pancreatic adenocarcinoma: a possible explanation for diabetes mellitus. Int. J. Cancer. (1996) 66(5):624-626.
   PubMed Web of Science ®Google Scholar
• FYSSAS I, SYRIGOS KN, KONSTANTOULAKIS MM et al.: Thyroid autoantibodies and thyroid function in patients with pancreatic adenocarcinoma. Acta Oncol. (1997) 36(1):65-68.
   PubMed Web of Science ®Google Scholar
• SYRIGOS KN, KONSTANTOULAKIS MM, CONSTANTOULAKIS M, MARAFELIA P, KOUTRAS D, GOLEMATIS BC: Thyroid autoantibodies and thyroid function in patients with gastric cancer. Acta Oncol. (1994) 33(8):905-907.
   PubMed Web of Science ®Google Scholar
• SCANLAN MJ, WELT S, GORDON CM et al.: Cancer-related serological recognition of human colon cancer: identification of potential and immunotherapeutic targets. Cancer Res. (2002) 62:4041-4047.
   PubMed Web of Science ®Google Scholar
• SOMERS VA, BRANDWIJK RJ, JOONSTEN B et al.: A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. J. Immunol. (2002) 169:2772-2780.
   PubMed Web of Science ®Google Scholar
• ANDERSON KS, LABAER J: The sentinel within: exploiting the immune system for cancer biomarkers. J. Proteome Res. (2005) 4:1123-1133.
   PubMed Web of Science ®Google Scholar
• FLAMINI G, CURIGLIANO G, RATTO C et al.: Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur. J. Cancer (1996) 32A:802-806.
   PubMed Web of Science ®Google Scholar
• KOZIOL JA, ZHANG JY, CASIANO CA et al.: Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin. Cancer Res. (2003) 9:5120-5126.
   PubMed Web of Science ®Google Scholar
• SYRIGOS KN, KARAPANAGIOTOU E, HARRINGTON KJ: The clinical significance of molecular markers to bladder cancer. Hybrid Hybridomics (2004) 23(6):335-342.
   PubMedGoogle Scholar
• SYRIGOS KN, PLIARCHOPOULOU K, HARRINGTON KJ: The development of monoclonal antibody therapy in leukemias. Hybridoma (2001) 20(3):145-148.
   PubMed Web of Science ®Google Scholar
• ZBAR AP, THOMAS H, WILKINSON RW et al.: Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a Phase I study. Int. J. Colorectal Dis. (2005) 20(5):403-414.
   PubMed Web of Science ®Google Scholar
• SYRIGOS KN, DEONARIAN DP, EPENETOS AA: Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer. Hybridoma (1999) 18(3):219-224.
   PubMed Web of Science ®Google Scholar
• SYRIGOS KN, DEONARAIN DM, KARAYIANNAKIS A, WAXMAN J, KRAUSZ T, PIGNATELLI M: Epithelial mucin expression in bladder cancer: correlation with pathological and clinical parameters. Urol. Res. (2000) 28(4):241-245.
   PubMed Web of Science ®Google Scholar
• SYRIGOS KN, EPENETOS AA: Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res. (1999) 19(1A):605-613.
   PubMed Web of Science ®Google Scholar